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This paper provides an overview of current progress in the technological advances
and the use of deep brain stimulation (DBS) to treat neurological and neuropsychiatric
disorders, as presented by participants of the Fourth Annual DBS Think Tank, which
was convened in March 2016 in conjunction with the Center for Movement Disorders
and Neurorestoration at the University of Florida, Gainesveille FL, USA. The Think Tank
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discussions first focused on policy and advocacy in DBS research and clinical practice,
formation of registries, and issues involving the use of DBS in the treatment of Tourette
Syndrome. Next, advances in the use of neuroimaging and electrochemical markers to
enhance DBS specificity were addressed. Updates on ongoing use and developments
of DBS for the treatment of Parkinson’s disease, essential tremor, Alzheimer’s disease,
depression, post-traumatic stress disorder, obesity, addiction were presented, and
progress toward innovation(s) in closed-loop applications were discussed. Each section
of these proceedings provides updates and highlights of new information as presented
at this year’s international Think Tank, with a view toward current and near future
advancement of the field.
Keywords: deep brain stimulation, Parkinson’s disease, Alzheimer’s disease, closed-loop, depression,
post-traumatic stress disorder, Tourette syndrome, DARPA
INTRODUCTION
The Fourth Annual Deep Brain Stimulation (DBS) Think
Tank convened in Gainesville, FL, on March 9–11, 2016.
In this summary we provide the meeting topics and
expert updates, as well as important highlights in each
area. DBS use has expanded in many neuropsychiatric
areas and there is a need for an interdisciplinary approach
incorporating neurologists, neurophysiologists, neuroscientists,
neurosurgeons, psychiatrists, rehabilitation specialists, ethicists,
members of industry, and engineers. The DBS Think Tank
aims to be an annual forum that facilitates sharing, discussing,
and debating the latest innovations and challenges in the field.
This year’s Think Tank focused on the regulatory process and
advocacy; innovative techniques and indications; updates in
the field of responsive DBS (closed-loop systems), as well as
updates on associated advances in electrophysiology and sensor
technology.
Abbreviations: 3-D, Three dimensional; AD, Alzheimer’s disease; ADD, Attention
deficit disorder; BCI, Brain computer interface; BLn, Basolateral nucleus of
the amygdala; CM, Centromedian thalamus; CMS, Centers for Medicare and
Medicaid services; CUA, Cost Utility Analysis; DARPA-SUBNETS, Defense
Advanced Research Projects Agency - Systems-based Neurotechnology for
Emerging Therapies; DBS, Deep brain stimulation; DTI, Diffusion tensor imaging;
ECoG, Electrocorticogram; EQ-5D, European quality of life 5 dimensions;
FDA, Food and Drug Administration; FDG, Fludeoxyglucose; GDP, Gross
Domestic Product; GTS-QoL, Gilles de la Tourette Syndrome quality of life;
HDE, Humanitarian device exemption; HFS, High frequency stimulation; HR-
QoL, Health related quality of life; ICER, Incremental cost effectiveness ratios;
IDE, Investigational device exemption; IIR, Investigator initiated research; IRB;
Institutional review board; LFP, Local field potential; LFS, Low frequency
stimulation; MCID, Minimal clinically important difference; mPFC, Medial
Prefrontal cortex; NINA, Neurological information non-discrimination act; NNTI,
National neurotechnology initiative; OCD, Obsessive-Compulsive disorder; PET,
Positron emission tomography; PTSD, Post-traumatic stress disorder; QALY,
Quality adjusted life year; QoL, Quality of Life; RNS, Responsive neurostimulator;
ROR, Right of Reference; SCC, Subcallosal cingulate; SF-36, Short-form 36-item;
STN, Subthalamic nucleus; TAA, Tourette Association of America; TRANSFORM
DBS, Transdiagnostic Restoration of Affective Networks by System identification
and Function Oriented Real-time Modeling in Deep Brain Stimulation; TRD,
Treatment resistant depression; TS, Tourette Syndrome; TSA, Tourette Syndrome
Association; UCSF, University of California at San Francisco; VNS, Vagal nerve
stimulator; YGTSS, Yale Global Tic Severity Scale.
The overarching goal was not to produce an evidence-based
summary or practice guidelines, but rather to engage participants
toward addressing and solving unresolved issues that impede
current and near-term research and translation of DBS. This
approach has the potential to expand collaborative research,
improve care and strengthen the field. The meeting, conducted
in a think-tank style, afforded equal time to key speakers’
presentations, and group roundtable discussions. The current
proceedings of the Think Tank provide a summary and review of
the developments, challenges, and opportunities in DBS research
and its clinical translation.
DEVELOPMENT OF AN INTERNATIONAL
REGISTRY AND DATABASE OF DBS FOR
TOURETTE SYNDROME
Update
Tourette Syndrome (TS) is a complex neuropsychiatric disorder
with multiple motor and vocal tics that can incur difficulty
with social engagement and communications that can often be
debilitating (Cheung et al., 2007; Kenney et al., 2008; Hanks et al.,
2015). DBS has been explored in a subset of TS subjects with
severely disabling symptoms. An international TS DBS registry
and database was established in 2012 by investigators in the
TS DBS field and the Tourette Association of America (TAA;
previously the Tourette Syndrome Association, TSA; Deeb et al.,
2016). The need for the registry and database was based on the
relatively low number of cases of TS patients who have received
DBS. The registry and database were therefore developed to
facilitate pooling information on these cases to define and refine
anatomical targets, develop management strategies, improve
therapeutic outcomes, inform, and support regulatory agency
approval, and ultimately, improve the quality of patient care.
Data are registered and securely stored at the University
of Florida, which serves as the hub site. The registry and
database enable collaborators to safely access and use the data
for research and practice improvement. The project collects cases
of TS who receive DBS from network sites, and encourages
investigators to submit complete treatment and follow up data on
every case. Data from multiple domains, including demographic
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information, pre- and post-operative clinical measures, surgical
measures, lead placement, DBS programming, and adverse events
are registered.
Multiple brain sites have been targeted for DBS in TS
(Figure 1; Malaty and Akbar, 2014).
By March, 2016 there have been 149 cases from 16 different
institutions registered. There were 94 cases targeting thalamic
regions (centromedian, parafascicular nuclei); 23 cases with
anteromedial pallidal targets; 41 cases with posteroventral
pallidal targets; and 2 cases with nucleus accumbens/ventral
capsular/ventral striatum targets. Interestingly, the age at the
time of surgery has been decreasing for TS DBS. This has
been reflected in development of revised guidelines, which now
no longer advocate that TS patients be a minimum age of
25 in order to be considered as viable candidates for DBS.
Indeed, TS patients younger than 18 years of age have had good
clinical outcomes following DBS treatment (Schrock et al., 2015).
However, data also reveal that multiple co-morbidities, including
obsessive-compulsive disorder (OCD), major depressive disorder
and attention deficit disorder (ADD), exist in the TS population,
and it is intended that the database and registry will provide
further information to elucidate how these conditions affect, and
are affected by DBS intervention.
To date, one of the most significant barriers to accruing
a relatively complete evidence base has been difficulties in
acquiring longitudinal datasets. Many records are missing
information regarding co-morbid conditions and motoric and
phonic tic follow-up scores at 6, 12, and 24 months. Additionally,
sub-score collection has been incomplete for tic scales (Yale
Global Tic Severity Scale YGTSS), and more data are required
on the actual DBS settings and their changes over longitudinal
follow up.
Developing a more finely grained understanding of the
problems with the technology, physiological effects, and adverse
events will be critically important to map the future of DBS
therapy, and new forms for effect and event recording matching
the Food and Drug Administration (FDA) standards have been
implemented. Adverse event reporting has included surgical,
psychiatric, cognitive and general events. Preliminary data
have revealed a higher than anticipated number of device
explantations and issues precipitating device removal and these
need to be further explored. Servello et al. (2016, 2011) have
shown TS DBS to be associated with increased infections and
hardware issues, but in some cases, the devices were removed due
to resolution of symptoms. In a limited number of cases, post-
operative lead location measurements have been made available,
and increasing such data will be important to the registry.
Multiple approaches have been suggested and implemented to
improve the collection of data across the numerous centers and
groups that provide DBS treatment for TS. For example, quarterly
reminder messages will now be sent to contributors in order to
acquire heretofore-missing data fields, and a dashboard has been
developed to allow secure, multi-site access to data.
The registry and database effort has been initially successful
in collecting information on safety of DBS in the TS population,
understanding preliminary effectiveness, and in driving better
outcomes. A planned objective is to explore if and how the
database could—and should—be utilized to inform and support
more a more facile method for obtaining of humanitarian
device exemptions (HDE), or other approval for DBS use from
other international regulatory agencies. Here a number of
key questions were posed that were regarded as important to
leveraging DBS in other potential areas of clinical application, as
well. These questions included: What obtaining HDE approval
would mean to scope and extent of research in the field. What
lessons can be learned from the OCD HDE experience? If
HDE approval does not prove to be a viable next step, how
might the registry and database be employed to help refine
large randomized clinical trials? What types of metrics [e.g.,
predisposing features; clinically response measures; quality of
life (QoL) indicators] will be important to characterize a good
responder? Is there a role for subjective narrative input from
each participating subject?
Highlights
- The TS DBS registry and database effort started in 2012 to
bridge the knowledge gap in the use of DBS in TS subjects.
- More consistent and extensive data collection is needed
to improve clinical outcome assessments, lead locations,
programming parameters and adverse event reporting.
- Future areas of effort include:
◦ Studying the viability and impact of obtainingHDE approval
in TS DBS and its implications.
◦ Characterizing TS subject phenotypes and meaningful
clinical metrics.
◦ Comparing outcomes of different surgical targets and
stimulation paradigms.
Registering Lead Locations and How to
Use the Data
The registry and database can serve as an expansive resource
of diverse types and levels of information that will be essential
to further define and refine the possible use(s) of DBS. For
example, there is an important role for data from functional
magnetic and diffusion tensor and kurtosis-imaging studies to
further systematically depict lead location(s), and changes in the
activity of anatomical nodes and tracts that may be involved in,
and/or subserve observed clinical outcomes and effects.
There are several laboratory-based tools for predicting and
reconstructing DBS effects. However, these tools are often
difficult to use and incur a relatively steep user-learning curve.
Developing simple systems to disseminate three-dimensional (3-
D) interactive models could provide means toward more useful
and user-friendly toolkits. One proposed approach toward this
objective is to incorporate plotting and predictive functions
into an interactive 3-D model. The method would employ
a visualization component that provides volume rendering
as well as surface renderings. The results would reveal the
effect-size on specific clinical outcomes (such as bradykinesia)
and would represent results as a function of stimulation-
location. The informatics component allows the user to use
a widget to query a position in space that will reveal
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FIGURE 1 | Schematic (cartoon) representation of potential therapeutic targets of DBS for Tourette Syndrome. Figure is not drawn to scale. ALIC, anterior
limb internal capsule (From Malaty and Akbar, 2014; with permission).
different visualizations of the outcome data associated with
stimulating a specific point in space. Clinical effect sizes
for various effects can also be extracted from the data
obtained.
A composite figure of actual lead locations in the subthalamic
nucleus was produced using data from a multi-center DBS
clinical trial. It revealed significant variability in lead location
and trajectory across the different centers, despite targeting the
same structure, and region (subthalamic nucleus). Analyzing the
variability in lead location will be critical, as it will allow more
accurate site specific correlation of lead placement and clinically
relevant (objective and subjective) effects of DBS in treating
different signs and symptoms of various disorders.
Future steps in developing imaging databases include
measures for insuring patient (and clinician) anonymity,
consideration of a data-use embargo period, and defining the
terms of use of information in the database. Participants in
the Think Tank proposed the possibility of a central data
repository of images and lead locations, to which practitioners
could upload individual scans to be used for comparisons and
benchmarks.
To be sure, the collection and assimilation of various types
and extent of data represent challenging tasks, and opportunities.
At present, a number of computational tools are available to
facilitate data collection and sharing. One such tool, developed by
the Center for High Performance Computing at the University
of Utah, enables use of a protected data environment platform
to allow collection of sensitive, personal health information. This
organized, scalable infrastructure can be used to host RedCap R©
and imaging software that enable differing types of data from
providers, patients, and caregivers to be entered and analyzed.
Ongoing efforts will be focused upon developing this and other
big data platforms to optimize collection, integration, use, and
modeling of diverse information.
Highlights
- Any database effort needs to establish the short-term, medium
term, and long-term goals.
- Lead location in the TS DBS database effort is a bedrock in
understanding outcomes.
- Steps are needed to improve collaboration and eliminate
obstacles.
◦ Tools are available to facilitate sharing of interactive and
predictive 3-D models.
◦ The think tank participants recommended the development
of a central data repository of lead location images.
Quantifying Economic Impacts of Deep
Brain Stimulation
Since 1999, a small number of patients worldwide have received
DBS for severe TS (Ackermans et al., 2008). Although, clinical
results have been promising, establishing clinical effectiveness
is not always sufficient to ensure investment in new medical
technology.
The Center for Movement Disorders and Neurorestoration at
the University of Florida maintains an international database of
patients with severe TS who have received DBS (n≈ 150). While
clinical data is collected pre- and post-DBS, to date economic
data have not been collected. When medical treatments must
compete aggressively for a limited pool of healthcare resources,
well-designed economic evaluation is essential to ensure that
necessary resources are directed toward treatments that offer
the best outcomes. In light of this, a comprehensive economic
evaluation of DBS for TS is planned.
A survey of patients and treating medical practitioners
will be undertaken to collect data necessary for economic
evaluation. Patients will be surveyed for indirect medical costs,
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including workforce participation and health related quality
of life (HRQoL) using a validated instrument (e.g., SF-36 or
EQ-5D). The treating medical team will be asked to report
direct medical costs and relevant post-operative clinical data
(e.g., verification of the neuroanatomical location of the DBS
electrodes, etc.). Direct medical costs will include the costs of
DBS hardware, surgery, inpatient stay, neurostimulator titration,
and post-operative complications. Quality-adjusted life years
(QALYs), a generic metric of HRQoL, is routinely used as a
summary measure of health outcomes in cost-utility analyses
(CUA) (Drummond et al., 2015). A QALY of one denotes a year
of life lived in perfect health. Years lived in less than perfect
health are scored less than one. Health policy analysts deem cost
per QALY ratios, less than some designated threshold, as being
cost effective. Thresholds between nations will vary, and can be
approximated by the gross domestic product (GDP) per capita
(Marseille et al., 2015). For example, ratios of US $50,000 per
QALY (Grosse, 2008) and £20,000–£30,000 per QALY (McCabe
et al., 2008), are used in the United States and United Kingdom,
respectively. Post-operative QALYs will be derived from reported
HRQoL sub-item scores. Pre-operative QALYs will be hindcast,
using coefficients obtained from statistical analysis, which regress
clinical variables on post-operative QALYs (Dodel et al., 2010;
Müller-Vahl et al., 2010). Costs and QALYs will then be analyzed
and incremental cost effectiveness ratios (ICERs) reported.
Other methods of analysis, such as the Minimal Clinically
Important Difference (MCID) may be valuable. We believe that
such findings will represent an important first step to elucidating
health outcomes’ afforded by DBS, and to informing appropriate
investment in DBS technologies and practices.
Highlights
- It is planned that economic data should be collected to establish
the cost-effectiveness of DBS as a treatment for severe TS.
- Technical (e.g., post-operative electrode placement), as well
as direct and indirect health costs plus a generic measure of
HRQoL data should be collected.
Regulatory Processes and Translational
Viability: Time for a Change?
Investigational Use of DBS in Clinical Practice
The overarching goal of the US Food and Drug Administration
(FDA) regulation process is to establish that any and all drugs and
devices provided for medical care are safe and technically sound.
In the United States, device trials utilizing either a non-approved
or an approved device to be used for a non-approved indication
require an investigational device exemption (IDE) to be granted
from the FDA. Failure to obtain an IDE will preclude most
Institutional Review Boards (IRBs) from approving prospective
studies of off-label use of devices. Both the IDE and HDE entail
considerable detail in scope, application, review and guidance,
and such stringency is necessary and important to determine
and to assure probity in applications of technology. Moreover,
whereas IDEs can be obtained (by industry) for industry-
sponsored device trials, investigators are required to obtain the
IDE in non-industry sponsored trials; this can be- and frequently
is—an arduous, and time- and cost-expensive process.
In recent years, IDE and HDE applications, review and
approval have become considerably more facile and efficient; this
is a notable improvement—and a step in the right direction.
However, as regards to DBS, it may be that aspects of the overall
structure and certain specifics of the IDE and HDE are not
well suited to meet the contingencies (and exigencies) of actual
clinical use, particularly in light of interest in exploring if and
how DBS may be of clinical benefit in the treatment of an
expanding number of neuropsychiatric conditions (as detailed
elsewhere in this report). For example, the current regulatory
framework necessitates filing and securing an IDE as a first step
in investigator-initiated research (IIR) and/or other off-label use
of DBS in those cases where other approaches have been shown
to be ineffective or untenable, and for which DBS may prove
to be viable as “humanitarian care.” In such instances, it may
be that the proverbial cart precedes the horse, and the HDE
might be more practical and valuable given both the nature of the
disorder and treatment, and the value of the HDE in establishing
a basis for further (and/or expanded) application, as supportable
by an IDE.
Moreover, while both IDE and HDE establish parameters
for using DBS in practice, neither regulatory mechanism
establishes or enforces a basis for provision of economic support
necessary for right and good use-in-practice. As recent work
has demonstrated, non-payment of insurance costs for pre-
certified DBS interventions has been, and remains a problem
of considerable concern (Rossi et al., 2016a,b). Absent resources
to provide: (1) DBS as a demonstrably-important or necessary
treatment option for those subjects with conditions that are non-
responsive to, or not candidate for other therapeutic options, and
(2) continuity of clinical services as required, the sustainability
of this neurotechnology may become questionable (Rossi et al.,
2014). We see this as contrary and counter-productive to recent
federal incentives to maximize benefits of translating extant and
new neurotechnologies into clinically-relevant and affordable
care and to implementing precision medicine.
In the main, we applaud actions taken by the FDA to date
that have streamlined the IDE and HDE process. Yet, while
certain aspects of the IDE and HDE mechanisms may be in
order, apt, and valuable for regulating use of DBS, others may
require re-examination, revision or replacement, so as to remain
apace with developments in the field, and needs and necessities
(of both subjects and clinicians) in practice. In this vein, we
recommend further study of: (1) the scope and tenor of the
IDE and HDE mechanisms to determine their independent and
interactive benefit (as noted above); (2) whether and which
aspects of the current IDE/HDE process are effective and
efficient, and which are not; (3) what aspects need to be retained
and fortified, revised or replaced; (4) what is entailed in these
revisions/replacements; and (5) if and how regulatory, policy and
legal processes can and should be aligned with, directive toward,
and supportive of and by concomitant changes in standard
of care guidelines and federal insurance structure (Fins et al.,
2012). A number of possible alterations to the IDE process
were addressed, which may streamline application and granting
of regulatory approval. These include: removal of the right
of reference letter (ROR) requirement; improved alignment of
federal grant mechanisms and regulatory process, and institution
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of mechanisms for Centers for Medicare and Medicaid Services
(CMS) and private insurance payment to support costs incurred
by patients involved in these trials. Proposed alternatives to IDE-
sponsored trials were also addressed, including the viability and
value of retrospective analyses of multiple case series, and large
scale, multi-site single case analyses, which could be facilitated
through the use of currently available computational tools
(e.g., the AvesTerra System; see: http://osvpr.georgetown.edu).
that enable massive data assimilation and integration, both
in concert with, and independently of a registry mechanism.
Important to this effort would be the development of both a
governmental-commercial enterprise to guide industrial efforts
in neurotechnology (e.g., a National Neurotechnology Initiative;
NNTI), as well as the establishment and enactment of federal laws
(e.g., a neurological information non-discrimination act; NINA)
to govern potential use(s) of information obtained through DBS
and related neurotechnologies together with extant and novel
big data initiatives (Kostiuk, 2012; DiEuliis and Giordano, 2016).
We believe that while establishing this “translational estate” will
require significant effort; it represents a worthwhile endeavor
toward the achievement of genuine and durable progress in the
development and use of neurotechnology in clinical practice.
DBS INNOVATIONS
Tourette Syndrome
As noted, much of the more innovative work to date has
(and remains) focused upon studying the viability and value
of DBS for the treatment of Tourette syndrome. While the
exact causes of TS remain unknown, recent neuropathology
neuroanatomical investigations have collectively implicated
dysfunction of corticostriatal and thalamocortical circuits
thought to play a role in the generation of abnormal motor
programs, possibly due to aberrant thalamic disinhibition (Albin
andMink, 2006). The collection of neural activity from the awake
and behaving human TS patients will offer new and vital insights
to the underlying neurophysiology of tic generation. To this end,
next generation DBS devices, such as the Neuropace RNS and
Medtronic Activa PC+S enable recording of electrophysiological
signals from both the implanted depth electrodes, as well as
acutely placed electrocorticography (ECoG) strips.
An unpublished study was presented that examined the
effects of DBS on two patients with severe, medication refractory
TS. Patients were implanted with bilateral Medtronic Activa
PC+S devices. Depth leads were placed in the centromedian-
parafascicular nucleus of the thalamus (CM) and ECoG strips
were placed over the precentral gyrus to cover the hand
primary motor cortex (M1). Experiments consisted of separate
interleaved trials in which patients were instructed to: (1) tic
freely, (2) suppress tics (baseline), and (3) execute volitional
movements (e.g., shaking hands rapidly, opening and closing
hands, raising arms up, and down, talking). Post-operatively
recorded data suggested that M1 yields a general motion detector
(15–30 Hz), whereas CM yields tic-specific features (1–10 Hz).
A human tic detector, based on support vector machines was
constructed during each post-operative visit (for a period of 6
months). Three types of tics were recorded including simple,
complex, and long complex tics. Long complex tics were shown
to be concurrent with a consistently detectable thalamocortical
signature. Short complex tics were more difficult to detect
than long complex tics, and simple tics were the most difficult
to detect. Acute trials of closed loop stimulation using the
Medtronic Nexus-E platform are currently underway. The
proposed system is presented in Figure 2.
Highlights
- The initial RNS study in TS patients revealed that good benefit
in tic control can be achieved with scheduled stimulation as
compared to continuous stimulation.
- LFP-ECoG neurophysiological testing identified a correlation
between tic activity and appearance of a 10 Hz narrow band
signal.
- Targeted stimulation using the 10Hz band as signal resulted in
tic improvement (preliminary results).
Summary of Use of DBS to Treat Epilepsy
Epilepsy, the result of the hyper-synchronization of firing
of neurons, creates “fragile” neurological networks that tend
to cycle. Multiple modalities of neurostimulation have been
developed to modulate burst and cycling activity in epileptic
patients (Krishna et al., 2016). In addition to DBS, techniques
such as vagus nerve stimulation (VNS), which engages afferents
of peripheral nervous system input to activate vagal pathways,
can alter firing patterns of brain networks involved in ictal
discharges and cycling. As well, the use of other neuromodulatory
techniques, such as responsive neurostimulation (RNS), has been
explored (Chang et al., 2015).
These approaches differ in their modulatory effects upon
cycling time, burst duration, frequency, and amplitude. In
addition, the locations of the VNS and DBS electrode placement
(at the anterior nucleus of the thalamus) are the same in all
patients while RNS employs a variety of possible placement sites.
The site of RNS is dependent upon identifying the epileptogenic
locus of nodes involved in a specific patient. In most cases, this
has been shown to be cortical gray matter. However, patients
with long-standing refractory epilepsy have been shown to
develop areas of secondary epileptogenesis, possibly through
kindling. To better manage multiple epileptogenic loci in this
population, stimulation of the affected circuitry (white matter)
rather than the epileptogenic gray matter is being considered
(Girgis and Miller, 2016). In these studies, it has been shown
that microelectrode recording and modification of the area of
stimulation can achieve differential, acute and chronic effects
on the involved neurocircuitry. Chronic effects appear to be
related to stimulation-induced plasticity, andmay engage trophic
mechanisms in that they subserve (at least some component of)
the therapeutic outcomes of neurostimulation in this patient
population.
Highlights
- Studies of the mechanisms and effects of DBS in treating
epilepsy can be useful to both an expanded understanding of
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FIGURE 2 | Diagrammatic depiction of the University of Florida approach to implementing chronic responsive DBS therapy for Tourette Syndrome.
Current experience with two patients with TS, who received bilateral centromedian (CM) thalamus depth leads and bilateral subdural grid implantation over their hand
motor cortex (A), led to the discovery of tic specific features in CM thalamus (1–10Hz) and motion detection features in hand motor cortex (15–30Hz; beta rhythm)
(B). A combination of these two features yielded highest detection of tics and differentiation from voluntary movements in linear discriminant analysis classifiers (C).
These classifiers are embedded in PC+S and send control signals to Nexus- E stimulation engine (D). Once the detectors sense presence of tic related activity,
stimulation will be activated to deliver stimulation to optimize therapeutic effects/outcomes.
DBS and brain pathology, and can synergize the development
of other types of neuromodulation.
- Studies of DBS (and VNS and RNS) reveal the importance of
determining and identifying anatomical targets (gray matter)
vs. circuit targets (white matter).
- Brain stimulation can exert acute and chronic effects, the latter
being related to neuro-plasticity and trophic effects.
- The role of multi-site, multi-electrode pre- and intra-operative
recording is essential to advancing understanding and
improvement of neuromodulation approaches to the treatment
of epilepsy; however, how findings from studies of the use of
DBS, VNS, and RNS may translate to broader applications of
these techniques remains a subject of continuing speculation.
Novel DBS Settings—Biphasic Pulses and
Beyond
DBS signal delivery is a rapidly progressing field. Recent
innovations in DBS signal delivery (Fasano and Lozano, 2015)
include regulated current vs. regulated voltage waveforms
(Lempka et al., 2010; Preda et al., 2016), differing stimulation
waveforms (Foutz and McIntyre, 2010; Wongsarnpigoon and
Grill, 2010), and different temporal patterns of stimulation
(Brocker et al., 2013; Adamchic et al., 2014).
Studies have repeatedly demonstrated the enhancement of
the therapeutic window with lower DBS pulse widths (Moro
et al., 2002; Volkmann et al., 2014). High frequency stimulation
(HFS; >100Hz) has generally been considered to be effective for
mitigating certain signs and symptoms of Parkinson’s disease
(PD), but low frequency stimulation (LFS; <100Hz) has yielded
contradicting results. LFS <50Hz has been shown to be harmful
resulting in worsening bradykinesia and tremor (Moro et al.,
2002). Stimulating at individualized gamma frequencies (30–
90Hz) improved PD symptoms, with outcomes that were similar
to those produced by HFS (Tsang et al., 2012). These findings
suggest that LFS can be effective provided that it is appropriately
matched to subject’s individualized gamma frequency patterns
associated with movement. Irregular patterns of stimulation
have also been studied in computational models, non-human
primates, and human patients. While there are some irregular
patterns that seem to be as effective as—or more effective
than—regular HFS, evidence for human testing remains limited.
A recent randomized, blinded pilot study of nonconventional
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DBS patterns and pulses—the first reported study of its kind—
tested 3 essential tremor and 8 PD clinically-optimized patients
in a clinic setting (Akbar et al., 2016). Of the settings tested,
the nonconventional biphasic pulse (equal and opposite, active
recharge phase) was shown to bemore effective than the clinically
optimized settings. Of course, it may be premature to draw firm
conclusions about the effectiveness of this pulse shape based
upon the results of this small pilot cohort, but such findings are
both of great interest and promising in their implications for the
viability and effectiveness of novel pulse and pattern parameters.
Additional studies to further investigate these possibilities and to
address the potentially short washout interval are underway.
Highlights
- A number of techniques of stimulation are available including
differing stimulation waveforms and current.
- There is a differential therapeutic effect of the various
stimulation parameters in DBS that appears to be related
to the underlying disease process (e.g., PD, dystonia). A
recently published pilot trial to assess different stimulation
parameters in PD and essential tremor subjects revealed
significant improvement induced by symmetric biphasic pulse
stimulation.
- Ongoing unresolved issues include the effect of differing pulse
and pattern settings on battery drain, requisite washout time,
and biophysical changes induced in affected neural nodes and
circuits.
Development of DBS Sensors
DBS surgery provides an investigational opportunity for use of
electrophysiological and/or neurochemical recording techniques.
Such approaches can: (1) aid in DBS lead placement, (2) provide
additional information about disease states, and (3) potentially
enable future development of techniques to better control
and fine-tune DBS therapies including closed-loop control
(Herrington et al., 2016). In addition, DBS surgery provides a
vector to introduce stem cells, autologous transplants, and/or
gene modification. We have termed the conjoined use of these
approaches DBS Plus.
Future directions in DBS have been proposed to incorporate
real-time monitoring of field potentials/unit activity, and in vivo
assessment of neurotransmitter release and turnover (Paek et al.,
2013). Such combinatory approaches could be used to further
define brain networks affected in disease processes, which could
serve to elucidate target sites for current and future applications
of DBS (including closed-loop systems) to more effectively—
and automatically—program, control, and modify stimulation
parameters (Grahn et al., 2014).
These iterations are currently under development. For
example, RNS for epilepsy and a new DBS variant manufactured
by Medtronic, the Brain Radio, implement simultaneous field
potential recordings that are coupled to neural stimulation. The
use of simultaneous DBS and neurotransmitter measurement is
being studied by Lee and coworkers in a Phase I investigation
using fast-scan cyclic voltammetry recordings coupled to carbon
fiber or boron doped diamond-like carbon microelectrodes
(Bennet et al., 2016). Gerhardt, van Horne and colleagues
are investigating (personal communication) the possible use
of glucose and glutamate as chemical biomarkers for control
of DBS. Current preclinical studies support that oxygen and
glutamate measures can be used to reveal both tonic and
phasic changes in neuronal systems that may be indicative of
trait- or state-dependent properties (Stephens et al., 2014). A
persistent technical impediment to these types of studies is the
difficulty of long term monitoring of neurochemistry in vivo.
As well, it remains unclear if and how in vivo neurochemical
monitoring can be durably yoked to DBS. The combined use
of electrophysiological recordings and real-time neurochemical
monitoring show considerable value for closed-loop control
of RNS technology for epilepsy, and for closed-loop control
of DBS therapy for PD. Nevertheless, given the early stage of
these developments, it will be important to continue studies
of real-time neurochemical monitoring for use in both open-
and closed loop DBS applications pursuant to advancing these
approaches toward more broadly applied clinical translation.
Highlights
- We introduce the concept of DBS Plus to describe the
incorporation of additional treatment and recordingmodalities
(e.g., stem cells, gene modification, neurochemical monitoring,
etc.) during DBS surgery.
- Multi-modality monitoring can be important to identifying
neural circuity involved in various pathologies and DBS effects,
and in these ways can facilitate more accurate electrode target
placement.
- These DBS Plus approaches show promise in the further
development of closed-loop systems.
DBS for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia
worldwide (Scheltens et al., 2016). Current focus of treatment
for AD treatment has pharmacotherapy aimed at modifying
acetylcholinesterase activity, N-methyl D aspartate receptor
activation, and more recently, production or deposition of beta-
amyloid or tau proteins. The limited evidence for symptomatic
benefit or slowing of disease progression from these approved
and investigational treatments, as well as the side effects reported,
support pursuing other avenues of intervention (Winblad et al.,
2016).
The importance of developing approaches to modulate
cortical and hippocampal circuits affected in AD was the
impetus for a phase I study of DBS targeting the fornix (Laxton
et al., 2010). The choice of the fornix as the target was based
upon serendipitous observation of improved spatial and verbal
learning and memory functions in patients who received DBS
leads in the hypothalamus for obesity management. In the
phase I study, continuous fornical stimulation produced
sustained increases in cortical metabolism at 1 month
and 1 year post-operatively. Further, increased functional
connectivity was observed in two orthogonal networks: a
frontal-temporal-parietal-striatal-thalamic network and a
frontal-temporal-parietal-occipital-hippocampal network. These
increases in functional connectivity were greater than effects
produced by 1 year of pharmacotherapy (with cholinesterase
Frontiers in Integrative Neuroscience | www.frontiersin.org 8 November 2016 | Volume 10 | Article 38
Deeb et al. Fourth DBS Think Tank Proceedings
inhibitors) and were in contrast to metabolic reductions and
decreased functional connectivity seen in the 1 year course of
AD. Higher cortical metabolism prior to initiation of DBS, as
well as increased metabolism after 1 year of DBS, were correlated
to better outcomes in global cognition, memory, and quality of
life indices (Smith et al., 2012). A multi-center, double-blind,
randomized, and controlled Phase II trial of 42 mild probable
AD patients—the ADvance trial—was conducted (Lozano et al.,
2016). In this study, the mean age of subjects was 68.2± 7.8 years
(younger than the AD population, but similar to the age range
of AD patients enrolled in clinical trials; Leinonen et al., 2015).
Average disease duration since diagnosis was 2.3 ± 1.7 years.
Electrodes were implanted in all patients, but half of the patients
did not receive stimulation for the first 12 months, and were
subsequently crossed over to active stimulation. The trajectory
was trans-ventricular and implantations of Medtronic hardware
were bilateral (Ponce et al., 2016). Stimulation was applied using
extant PD protocols, with a frequency of 130 Hz, pulse width of
60µs, and voltage set at 50% of that at which side effects (e.g.,
autonomic or cognitive changes) were seen, with a maximum
test voltage set at 7 V and maximum continuous voltage of 3.5
V. There was no noted acute decline in cognition after 1 month
of surgery. Consistent with results of the prior Phase I study,
persistent increases in metabolism were observed in the group
receiving stimulation (i.e.,- the ON group) after 6 and 12 months
of DBS of the fornix, in contrast to the OFF group that showed
decreased metabolism (7–13%) across all regions assessed. The
primary goal was safety; the safety profile of the procedure was
acceptable and comparable to pharmacologic therapies. There
were some short-term side effects related to the surgery, as well
as some psychiatric side effects (as expected following DBS).
None of the subjects had persistent side effects or complications
at 12 months follow-up.
Secondary goals were to evaluate the preliminary efficacy of
therapy. These secondary end points were notmet, although post-
hoc analysis of subgroup evaluations based upon age showed that
when patients 65 years of age or older were analyzed separately,
greater increases in metabolism were observed in the ON group
compared to those under age 65 (14–20% across regions over
age 65). The subgroup aged <65 years had worsening clinical
scores, while the subgroup aged >65 years showed improvement
in clinical scores. The clinical scores used for this analysis
included the Clinical Dementia Rating (CDR) and Alzheimer’s
Disease Assessment Scale—cognitive subscale (ADAS-Cog). In
this older cohort, increased metabolism with fornical DBS was
observed in the temporal and parietal cortices and hippocampal
regions affected by AD, as well as in sensory and motor cortical
regions that are relatively spared in this disorder. Functional
connectivity and correlational analyses are currently in progress
to determine the networks affected by DBS that are involved with
clinical improvement, and the relationship between themetabolic
and structural brain alterations associated with DBS to the
fornix.
Other potential targets for DBS treatment of AD have been
assessed and include the nucleus basalis of Meynert and the
entorhinal cortex. Further studies are needed to: (1) clarify
stimulation parameters for various brain regions and networks
that can be targeted to mitigate signs and symptoms of AD; (2)
define mechanisms through which DBS produces therapeutic
and side effects in AD patients, and (3) to enable more accurate
subject identification and selection.
Highlights
- DBS of the fornix has been shown in phase 1 studies to be
associated with metabolic and clinical changes.
- TheADvance trial, a recently completed phase 2 study, assessed
the safety of fornix DBS in AD, that demonstrated:
◦ No significant long-term complications,
◦ No acute cognitive decline after DBS surgery,
◦ Age-dependent effects with patients over age 65 achieving
better outcomes,
◦ Concerns about bilateral simultaneous implantation,
◦ The need to further identify “optimal” stimulation
parameters,
◦ Need for further study before considering fornical DBS as a
viable treatment for AD in clinical practice.
CLOSED-LOOP DBS
Introduction
Existing DBS devices continuously stimulate their target
structures regardless of the actual level of pathological
activity. This can result in stimulation induced adverse effects,
habituation, short battery life, and the need for labor-intensive
programming sessions by a neurologist. Closed loop DBS
enables simultaneous feedback and feedforward control of
stimulation parameters that can afford a high level of precision
and individual modification to variations in brain state. A
major consideration of closed loop DBS is determination of the
input signal. Recording brain signals in different therapeutic
conditions (on and off DBS; on and on medication) has led to
a better understanding of pathophysiology underlying PD, TS
(discussed above) and major depression. This work results in the
identification of disease markers that might be used as control
signals for closed-loop DBS algorithms.
Parkinson’s Disease
Published work has focused on the use of a beta-band signal
(13–30Hz) as a control signal (Little et al., 2013). However,
the beta band is somewhat limited as a control signal by the
influence of normal movement upon the signal fidelity. In light
of this, current work is aimed at identifying oscillations that are
outside of the beta-band that may be useful as markers. One,
a narrow band gamma signal that has been defined as between
60 and 90 Hz, has been previously assessed as a surrogate signal
using local field potential measurements (LFP) of the subthalamic
nucleus (STN) (Brown et al., 2002; Cassidy et al., 2002). However,
further study is required to more fully define the value of this,
and other signals that can be utilized for optimized closed-loop
control. Pursuant to such study, extensive neurophysiological
work will be required.Work currently underway involves cortical
recording with ECoG at the precentral gyrus/primary motor area
and depth electrode recording at the level of the basal ganglia.
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For example, to assess control signals in PD subjects
with dyskinesia, researchers at the University of California at
San Francisco (UCSF) group have implanted 5 patients with
Medtronic Activa PC+S neurostimulators attached to a DBS lead
(Medtronic 3389) in the STN and a 4-contact cortical ECoG strip
(Medtronic Resume paddle) placed over the M1. Cortical and
subcortical signals were collected over 2 years while patients were
on and off therapeutic DBS as well as on and off dopaminergic
therapy. During these recordings patients were resting with eyes
open or engaged in a cued arm-reaching task (de Hemptinne
et al., 2015). M1 and STN signals were recorded in a bipolar
configuration at 800 Hz, stored and the PC+S downloaded non-
invasively via telemetry and analyzed in the frequency domain.
Using this unique data set (unpublished data), they found that
periods of dyskinesia are associated with an increased neuronal
synchronization in the gamma band (60–90Hz; Figure 3). This
excessive synchronization is reflected as a narrow band peak
in the spectral power density of both M1 and STN signals,
although less reliably detected in the latter. The emergence of
this excessive synchronization occurs only in the presence of
dyskinesia suggesting it as a marker of dyskinesia rather than
a marker of the dopaminergic state. Interestingly, the cortical
narrow-band gamma signal was shifted to half of the stimulation
frequency when DBS was turned on, in the presence of dyskinesia
only, which might be explained by a partial entrainment of
axonal activity to stimulus pulses (Li et al., 2012). Contrary
to broadband gamma activity, a non-oscillatory signal strongly
affected by movement, the narrow-band gamma signal studied
here was independent of the subject’s “normal” voluntary non-
dyskinetic movements. Othermarkers were studied including the
coherence between the cortical and basal ganglia signal, as well as
phase-coherence (unpublished data).
Narrow gamma band signals are part of a normal motif in
brain connectivity allowing communication between multiple
brain areas and alteration of these oscillations might results in
dyskinesia as suggested by this study. Recordings in the motor
cortex of a rodent model of PD identified a remarkably similar
phenomenon in dyskinetic rats versus non-dyskinetic animals
(Halje et al., 2012).
FIGURE 3 | The graphs depict the results of analysis of the M1 signal in
the frequency domain in PD patients with dyskinesia. It shows, in the
graph on the left, that dyskinesia is associated with an increased neuronal
synchronization in the gamma band (blue line) reflected as a narrow band
peak. The graph on the right shows that this gamma-band signal is related to
dyskinesia and independent of the functional state (rest, walking, or voluntary
arm movement).
Given the predictable frequency at which this marker occurs,
the simple method used to calculate it and the small impact of
stimulation artifact of cortical signals, this biomarker is the ideal
candidate to develop a closed-loop DBS algorithm. Therefore,
the next step of this study is to develop closed-loop paradigms
using this narrow-band gamma signal as a control signal and
test it in PD patients with dyskinesia using the Medtronic Activa
PC+S with the Nexus-D and E updates that allow for real time
sensing and stimulation updates.
Highlights
- The use of beta-band subcortical oscillations in PD as a control
signal is limited by the effects of voluntary movements and
stimulation.
- Narrow gamma-band signal (60–90 Hz) appears to correlate
with the dyskinetic state in PD subjects, is less affected
by stimulation artifact and is independent of voluntary
movements.
- Ongoing study to use the identified narrow gamma-band as
a control signal for closed-loop DBS in PD patients for better
control of dyskinesia.
Depression
It has been ∼10 years since the first proof-of-principle report
supporting the efficacy of subcallosal cingulate (SCC) DBS to
reduce signs and symptoms of treatment resistant depression
(TRD; Mayberg et al., 2005). Initial selection of the SCC as
a putative DBS target was principally based on converging
findings from resting-state positron emission tomographic (PET)
imaging studies of conventional antidepressant interventions,
localization of depression-related circuits, and nodes using
standard structural imaging methods, and trial-and-error
behavioral testing of chronic stimulation at individual contacts
on each implantedDBS electrode. As testing of DBS for treatment
resistant depression has matured and expanded, neuroimaging
continues to play a crucial role, with recent work now focused
on refinement and optimization using multimodal methods
combined with real-time behavioral and physiological metrics.
These combinatory approaches affordmore precise identification
of optimal target locations in real time (Smart et al., 2015).
One proposed mechanism of DBS in reducing features
of treatment resistant depression is modulation of a multi-
region network converging at the SCC (Figure 4). Structural
connectivity analysis of SCC DBS confirms the SCC as a
critical node within this specified “network,” as small differences
in stimulation location can generate substantial differences in
activated fibers. Recent studies have further confirmed which of
these pathways are necessary for clinically significant effects of
DBS. These pathways can now be prospectively characterized
in individual patients using DBS parameter models coupled to
structural connectivity analyses (Riva-Posse et al., 2014; Choi
et al., 2015).
Close clinical monitoring and systematic long-term follow-up
using small experimental cohorts outside of industry-sponsored
trials have further provided new perspectives on the time course,
trajectory and sustainability of DBS-mediated effects (Crowell
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FIGURE 4 | The panes depict (from left to right) the evolution of surgical targeting of SCC in depression from, an anatomical “gray matter” target to
identification of the “white matter” tracts activated, and finally tractographic data allowing identification of the involved pathways that elicit differing
effects when targeted by DBS. This approach allows individualized target refinement and produces improved therapeutic outcomes. Genu, genus of the corpus
callosum; Mid-SCC, mid subcallosal cingulate; Ac, anterior commissure; mF10, medial frontal Brodmann Area 10; ACC, anterior cingulate cortex; aTh, anterior
thalamus; vSt, ventral striatum; Fr-st, frontal striatal fibers.
et al., 2015). Notably, patients often experience contact-specific
changes in mood, attention, psychomotor speed, and autonomic
reactivity with initial testing during electrode implantation
surgery. Importantly, these acute behavioral effects appear
predictive of long-term response. Recent implementation of
real-time recording of SCC LFP during acute testing and ongoing
therapeutic DBS using the prototype Activa PC+S DBS system is
providing a first-in-human view of differential SCC LFP changes
mediating immediate, sub-acute, and chronic DBS-induced
antidepressant effects at the neural level. LFPs measured at
the site of stimulation combined with concurrent high density
EEG will further enable characterization of clinically relevant
network-wide effects. Findings from this small exploratory study
will potentially provide new metrics to further improve precision
of surgical targeting as well as new algorithms for DBS delivery
beyond current methods. Validation of relationships between
local and network-wide changes with the differential time course
of recovery in specific clinical features will lay the foundation for
sensing signals for next generation neurostimulation systems.
Highlights
- Initial selection of the SCC as a putative DBS target
was principally based on converging findings from resting-
state PET imaging studies of conventional antidepressant
interventions.
- Recent work now is focused on refinement and optimization
using multimodal methods combined with real-time
behavioral and physiological metrics, providing a more precise
identification of the optimal target location in real time.
- Modulation of a multi-region network converging at the
SCC is a proposed mechanism of action for DBS in reducing
features of depression.
- Validation of relationships between local and network-wide
changes with the differential time course of recovery in specific
clinical features will lay the foundation for sensing signals for
next generation neurostimulation systems.
Clinical Assessment and Management of
Tremor
Tremor-dominant PD patients have been shown to have a
functional correlation of their tremor and beta-band signals
as measured by LFP. The resting state beta band may be
attenuated during periods of tremor in PD. Resolution of tremor
results in re-emergence of the beta band (Little and Brown,
2012). This suggests that beta band power may be viable as a
kinematic control variable to drive closed loop DBS for tremor,
as diminished beta band power during tremor could be assumed
to signal a decrease in closed loop DBS. However, the activity-
dependent fluctuations in the beta-band power limit its use a
sole control for closed loop DBS in PD tremor. Bronte-Stewart
and colleagues (Malekmohammadi et al., 2016) reported the
efficacy of closed loop STN DBS to control resting tremor, using
a kinematic measure of tremor power from use of a wearable
Bluetooth enabled smart watch (LG G-watch; Figure 5).
In their study, baseline tremor recordings were performed,
from which maximum tremor power was calculated. Closed loop
DBS was driven by real-time measurement of tremor: when
tremor intensity exceeded 50% of the maximum baseline tremor
power, the control policy algorithm commanded an increase in
DBS voltage at a predetermined safe ramp speed; when tremor
intensity fell below 25% of the maximum tremor power, voltage
was decreased. Using this model it was noted that the rate
of change in stimulation voltage (if decreased quickly) could
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FIGURE 5 | (A) Example of adaptive stimulation voltage (top row) and tremor power with 25% (magenta) and 50% (cyan) thresholds of the control policy algorithm
(bottom row). Black horizontal lines above upper panel indicate timing of calibration and closed loop DBS (aDBS). Dashed black line shows level of clinical stimulation
voltage. (B) Comparison of mean tremor power at baseline and during aDBS across the group. (C) Comparison of average stimulation voltage during open loop
continuous (cDBS) and aDBS for the group. (D) Insert to (A) showing the timing of the aDBS decision tracking. When tremor power exceeded the upper threshold
(red triangles), the stimulation voltage increased. When tremor power fell below the lower threshold (blue triangles), stimulation voltage decreased. Stimulation voltage
remained unchanged if the tremor power level remained between lower and upper thresholds.
be correlated to occurrence of rebound tremor. Consequently
the rate of decreasing voltage was set at 0.5 times the ramp
(or increase) rate. Overall, the mean tremor power significantly
decreased by 36.6% (p = 0.014) during closed loop DBS, and
the mean voltage used was 76.4% lower than that used during
continuous open loop DBS (p = 0.02). On average, closed loop
DBS was “on” for only 51.5% of the time (p = 0.002), but there
was a significant variation among subjects in the duration and
average voltage required for effective stimulation.
This study provided proof of concept that real time
kinematic measurement of tremor represents a safe, tolerable and
efficacious method to drive STN DBS for tremor in PD. This
strengthens prior findings of pilot trials using a neural control
variable to drive closed loop DBS in the treatment of PD (Little
et al., 2013; Rosa et al., 2015), and provides further support for the
use of kinematic controls to supplement LFP input in developing
personalized closed-loop DBS systems.
Development and Use of Algorithms in Closed Loop
Systems—A Focus on Tremor
In current clinical practice, DBS treatment involves open loop
control. The stimulation parameters are pre-set for each patient,
and do not automatically adjust to the presence or absence of
symptoms, side effects or other patient-specific variables. The
result is excessive battery consumption, as well as the possibility
for undesirable side effects. Work by Chizeck and colleagues has
produced a platform for investigating the control of DBS (Herron
and Chizeck, 2014), which has now being employed by other
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groups. One mobile, wireless version consists of a set of worn
inertial and electromyography sensors that communicate via
Bluetooth to a host application running on a smartphone, smart
watch or laptop. Using sensed data, the host application initiates
control decisions, including enabling or disabling stimulation
or modifying individual stimulation parameters (voltage, pulse
width, frequency). These control signals are then transmitted
by Bluetooth to a Medtronic NexusTM system, which relays
packets and control on a hardware and software modification of
the clinician programming unit, driving a FDA approved and
implanted DBS system (the Medtronic Activa PC+S)TM (Herron
et al., 2015; Houston et al., 2015; Malekmohammadi et al., 2016).
An alternative, fully implanted system that is currently under
development uses implanted cortical electrodes (connected to
the DBS) to measure local field potentials (along with the deep
brain electrode), as indicators of tremor and/or patient intentions
and stimulation adjustment requests. These systems are being
evaluated on patients with essential tremor and PD (Houston
et al., 2015). This represents a practical implementation of a
brain computer interface—BCI (i.e., which can be used for
voluntary BCI-triggered stimulation adjustment by the patient;
Thompson et al., 2016). These platforms also provide an
opportunity for collection of tremor and stimulation data for
extended periods of time, which will be vital toward gaining
further insight to both the neurological basis of tremor, and
issues related to the long term viability and use of these devices
(Brown et al., 2016).
Highlights
- Activity-dependent fluctuations in the beta-band power in STN
limit its use a sole control for closed loop DBS in PD tremor.
- Kinematic input can be processed by a laptop or smartphone
that produces control signals that are then transmitted via
Bluetooth to a Medtronic Nexus
TM
system, which relays
packets and control on a hardware and software modification
of the clinician programming unit, driving a FDA approved
and implanted DBS system.
- Combination of kinematic input in a closed-loop DBS system
resulted in tremor control, but there was considerable variation
among patients.
- Future directions include the development of fully implanted
closed loop DBS systems.
Development of a Closed Loop System for
Tourette Syndrome






The goal of the Defense Advanced Research Projects Agency
(DARPA) Systems-Based Neurotechnology for Emerging
Therapies (SUBNETS) project is to develop closed-loop DBS
projects that will address the multiple neuropsychiatric problems
occurring in the veteran and general population, including
post-traumatic stress disorder (PTSD), traumatic brain injury,
depression, anxiety, chronic pain, and substance abuse. In a
recent article, Vigo and colleagues estimate from published data,
that the global burden of mental illness is 32.4% of years lived
with disability (Vigo et al., 2016).
Currently available treatments (e.g., pharmacological
and psychological therapies) can be helpful for some
patients. However, some patients are left with partial or
no response to such intervention(s). Brain stimulation
offers notable promise in treating these patients, as there
are already FDA approved indications for the use DBS in
treating other neuropsychiatric conditions such as OCD (see:
http://www.accessdata.fda.gov/cdrh_docs/pdf5/H050003b.pdf).
To address this clinical problem, DARPA currently supports East
Coast and West Coast Research Teams that are engaged in key
projects focusing upon one or more areas of state-of-the-art DBS
techniques and technologies. Sections East Coast Research Team
Updates and West Coast Research Team Updates summarize
their unpublished work.
East Coast Research Team Updates
Transdiagnostic Restoration of Affective Networks by System
identification and Function Oriented Real-time Modeling in
Deep Brain Stimulation (TRANSFORMDBS), the DARPA 5 year,
funded program at Massachusetts General Hospital (MGH) is
currently in its second year.
A recurring concern when attempting to categorize
neuropsychiatric disorders is that most patients have co-
morbid conditions that present with considerable variability.
To decrease the effects of co-morbidity on analysis, the
TRANSFORM DBS group employed a trans-diagnostic
FIGURE 6 | Vector diagram illustrating the difference between a
categorical diagnosis (in this instance MDD or major depressive
disorder) and a symptom based or behavioral based domain
assessment. The limitation of the categorical diagnosis analysis is that it can
average and thereby diffuse genuine subgroup (behavioral domain) therapeutic
effects.
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approach that focuses on behavioral domains rather than
categorical diagnosis or co-morbidity assessments (Figure 6).
Behavioral tests were developed to quantitate the severity
of each domain, and these findings were used to guide
treatment.
In collaboration with Draper Laboratory (Cambridge, MA),
the group developed a modular, flexible implantable system that
allows 320 simultaneous recordings. The identification of the
deep electrode implantation site is determined by structural and
functional assays relating to the different behavioral components.
Studies thus far have been on non-human primates, with plans
to extend investigations to humans in the epilepsy-monitoring
beginning in summer 2016.
West Coast Research Team Updates
Recent animal and human studies of brain connectivity have
fostered a mesoscale network approach to interpreting and
understanding mechanisms of neurocognitive function and
dysfunction (Yuste, 2015).
This network-based construct suggests that psychiatric
disorders may be related to changes in the function and/or
structure of particular neural nodes and inter-nodal connectivity.
Given the plasticity that has been demonstrated in neural circuity,
a basic premise of SUBNETS is that DBS can be employed as a
tool to facilitate re-modeling of brain architecture on micro to
mesoscales.
The West Coast Team—at the UCSF—presented their initial
work “mapping” the frontal and pre-frontal cortical areas by
advancing an electrode grid under intra-operative fluoroscopy in
PD patients undergoing DBS. At each cortical area, they stimulate
and record the electrophysiological and clinical changes (mood
states). The results show significant variability among patients,
but indicate a possible correlation between the recorded signals
and different mood states.
The next phase of this DARPA project will focus on chronic
recording and stimulation in PD patients who have moderate
psychiatric co-morbidities.
Highlights
- The goal of the DARPA’s SUBNETS project is to develop closed-
loop DBS projects for multiple high-burden neuropsychiatric
disorders: PTSD, anxiety, depression, substance abuse, and
pain.
- Two projects were discussed with different approaches in
identifying DBS closed-loop systems:
◦ East Coast Group
Using behavioral domains (avoidance, perseveration, etc.)
rather than categorical diagnoses (depression, anxiety,
PTSD, etc.) as endpoints.
Using a custom-built modular and flexible implantable
system allowing 320 simultaneous recordings.
Work so far has been on non-human primates with
human studies planned to start in summer 2016.
◦ West Coast Group
FIGURE 7 | Diagrammatic representation of a possible closed-loop
DBS system comprised of sensors (e.g., - ECoG, neurochemical
sensors and local field potential sensing through the implanted
electrodes) that influence the stimulator (actuator) signal. The sensed
signal is classified, and with use of an implementation algorithm, can influence
the stimulator output to induce therapeutic effects.
Using intra-operative grid mapping of the frontal and pre-
frontal cortical areas to assess their effect on affective states
in patients with PD undergoing DBS.
Noted significant variability among the different patients.
Work so far has been on intra-operative recording, next
phase will use chronic recordings.
DEVELOPMENT IN TECHNOLOGY AND
APPLICATION
Closed-Loop DBS
Much of the hardware of DBS technology has been adapted from
the cardiology field. A major limitation to ongoing refinement
of DBS technology is a somewhat limited understanding of
its mechanism(s) of action (Herrington et al., 2016). As noted
in Section Introduction, open loop DBS does not respond to
variations in the patient’s state and disease progression but
rather produces a pre-programmed output stimulation. This
can result in a suboptimal outcome as optimization of the
output stimulation has to be done by separate visits to provider
clinics, usually many weeks apart. The closed-loop DBS system
offers a solution by allowing integration of feedback signals
to continuously modulate the output stimulation using an
algorithm. The development of these advanced systems involves
the construction of a number of components that are reliant,
at least in part, upon feedback and feed-forward integration.
The system comprises sensors that are connected to an actuator
through a classifier and control policy (Figure 7).
Recent technological advances allow multi-modality sensing.
Many of these modalities were discussed in prior sections
and include LFP, ECoG, and neurochemical sensing modalities.
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There are multiple limitations to the current recording/sensing
implantable technology. One, the signal sensed and recorded by
implantable sensors has a lower quality than the one measured
by stand-alone devices that are non-implantable and can be
used only intra-operatively for a short period of time. Two,
the signal measured is of relatively low amplitude. Three,
identification of the appropriate signal to sense is still evolving
and not clear for most indications (refer to Sections Tourette
Syndrome, Development of DBS Sensors, Parkinson’s Disease,
Clinical Assessment andManagement of Tremor). Four, there is a
need to develop mechanisms to distinguish between the feedback
and stimulation signals.
The feedback signal is transmitted from the sensors to a
classifier system. The role of this system is signal processing,
converting the raw signal into classified data that will be
recognized by the algorithm. The latency of the signal
transmission for analysis, though improving, is still a limiting
factor in building closed loop DBS systems. The most complex
component of developing algorithms for closed loop DBS is to
modulate the output signal from the actuator (DBS stimulation)
in order to affect the outcome toward the desired state. This
is an area of considerable research. Section Clinical Assessment
and Management of Tremor exemplifies the development of a
classifier system based on the amplitude of the tremor and a
relatively simple algorithm that modulates the output signal.
As with any biomedical technology, safety is an important
aspect of closed loop DBS, and therefore a first objective is
determining safety limits for the algorithms. A second and
related consideration is the development of facile mechanisms to
allow the patient and/or clinician to deactivate the closed-loop
system, and/or engage a “default—safety mode” open loop
system.
Highlights
- The DBS field is moving from the use of systems of continuous
stimulation to more adaptive, closed-loop systems.
- To facilitate such progress, it will be important to address and
resolve a number of issues, including:
◦ Improving recording and feedback signal acquisition.
◦ Improving latency time from signal sensing to analysis.
◦ Developing classifier systems that allow signal processing.
◦ Generating valid and safe algorithms of closed-loop
function(s).
◦ Identifying markers of neural response.
◦ Identifying appropriate stimulation responses.
◦ Understanding and developing patient specific parameters
for precision closed-loop DBS.
Electrical Current Shaping
The most commonly used lead design in DBS systems includes
four (4) ring-shaped contacts. In monopolar settings, each
of these contacts produces a spherical electrical field. This
can be problematic in cases when the lead is not optimally
positioned in the target zone, as resultant stimulation induces
side effects evoked by stimulation of off-target tissue(s) (Deuschl
et al., 2006). To maintain clinical benefit while minimizing side
effects, practitioners tend to modify the shape of the electrical
field. Different approaches have been used, including bipolar
stimulation, double monopolar stimulation, and/or interleaving
settings.
Given the demonstrated importance of site and directional
specificity of DBS electrical fields, new lead designs that
allow current shaping/steering have been developed. The
“directSTIM” lead, a design by Aleva Neurotherapeutics
(Lausanne, Switzerland), divides each contact ring into 3
sub-compartments that can be individually stimulated (Hariz,
2014). Another, “SureStim,” developed by Sapiens (Eindhoven,
the Netherlands), has 32 contacts distributed evenly (Contarino
et al., 2014). A third, Vercise PC, produced by Boston
Scientific and recently approved for use in Europe (September
2015), uses an 8-contact directional lead—the VANTAGE study
(Timmermann et al., 2015). These designs allow current to
be shaped away from unintended targets while maintaining a
larger therapeutic window to the intended target site(s). Some
limitations to these designs arise from the electrical properties
of the system. For example, decreasing the surface area of the
active contact will result in increased impedance and therefore
increased power consumption. As well, impedance variation
between different smaller contacts will passively dictate current
distribution whenmore than one contact is simultaneously active
if independent current sources are not employed.
To date, published data, as derived from use of the
commercially available Vercise PC, has been limited to acute
intraoperative settings, with only limited information available
about the effects and efficacy of current steering in clinical care.
However, unpublished data were presented at the Think Tank
that illustrated the feasibility and improved therapeutic window
of steered current, STN DBS in PD patients using the Vercise PC
system in the clinic setting.
We posit that current steering/shaping approaches offer
promise to improve the clinical outcomes of DBS, by allowing
a wider therapeutic stimulation window, especially in those cases
where lead placement may be difficult, and/or less than precise.
For example, if a lead is targeting the STN in a PD patient
but was noted post-operatively to be more lateral than initially
planned, conventional stimulation will not only stimulate STN
but also the adjacent internal capsule. This will produce a low
threshold of stimulation to side effects thus providing only sub-
optimal control of PD symptoms. By steering the current away
from the internal capsule, a higher threshold of stimulation can
be tolerated resulting in a better clinical outcome (Hariz, 2014).
Highlights
- A challenge facing the use of conventional DBS leads is delivery
of the electrical current to the desired region while avoiding
side effects by stimulating undesired areas.
- One approach proposed to decrease the undesired area
stimulation is by using current steering
◦ Multiple lead designs are now being investigated.
- Unpublished results of prospective in-clinic current steering
testing were presented that showed improved outcomes with
STN current steering.
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Neurosurgical Technique Updates in DBS
The accuracy of surgical placement of the DBS electrode(s) at the
specified anatomical targets is important. Although stereotactic
techniques combining preoperative image-based planning
with intraoperative recording and test stimulation are well-
developed, these approaches carry risks including intracranial
hemorrhage (1–3% both symptomatic and asymptomatic with
<1% symptomatic), seizures (∼1%), leak of cerebrospinal fluid
(1–2%), and infection (2–3%) (Videnovic and Metman, 2008;
Patel et al., 2015). While rates of adverse events appear to be
quite low, in reality, these rates have been shown to increase to
∼5% when data are prospectively and systematically collected
(Burdick et al., 2010). Innovations in the surgical delivery of DBS
include the use of intraoperative magnetic resonance imaging
(Ostrem et al., 2013; Chabardes et al., 2015) to identify and
guide electrode placement, and the use of frameless stereotaxy
to enable more accurate surgical access and reduce burden and
risks incurred by the operative hardware (Khan and Henderson,
2013). These are yet nascent, and the benefit and effect(s) of such
innovations remains unknown.
Another surgical innovation in DBS lead implantation is the
development of intravascular DBS electrodes. The feasibility
of intravascular electrodes for both neural stimulation and
recording and stimulation has been demonstrated. Electrodes
positioned temporarily within intracranial vessels enabled
recording of both spontaneous and evoked EEG-like electrical
activity (Driller et al., 1969), and this work was recently extended
to multi-electrode recordings using a chronically implanted
stent-like device (Oxley et al., 2016). Stimulation through the
blood vessel wall is also possible, an example being endovascular
stimulation of the vagus nerve (Nabutovsky et al., 2007), and a
recent simulation analysis demonstrated comparable patterns of
model nerve fiber activation between an intravascular electrode
and traditional stereotactically-positioned DBS leads (Teplitzky
et al., 2014). This is not to suggest that intravascular methods
are without risk; however, such innovations may provide a
less-invasive approach to both record and stimulate deep in the
brain and thus, represent new way to deliver DBS.
Highlights
- Significant advances have improved neurosurgical techniques
of DBS implantation, but the complication rate remains∼5%.
- Intravascular stimulation may prove to be a viable, alternate
method for delivering DBS.
NEW CLINICAL APPLICATIONS OF DBS
DBS for Treatment of Addiction
This year, a case was presented at the Think Tank of a female
patient with severe OCD (displaying excessive cleaning behavior)
who gained appreciable therapeutic benefit (i.e.,—reduction of
compulsive behaviors and obsessive ideation) following nucleus
accumbens DBS (Mantione et al., 2010). Of particular note
however, was that this patient also was able to quit smoking and
lost an appreciable amount of weight (she was obese) following
DBS implantation. Although, it remained unclear whether these
latter two effects were directly due to DBS or were artifacts, it was
speculated that DBS may have effected change in neural circuitry
mediating obsessive ideation and/or compulsive-type behaviors
that subserve over-eating and smoking. The effect of the nucleus
accumbens stimulation on addiction (cigarette smoking) in this
OCD patient prompted interest in considering this target for
treatment of addiction without co-morbid OCD. This has been
reinforced by the identification of nodes and networks in the
brain associated with addiction (Volkow et al., 2016).
This has prompted a funded trial of DBS targeting the
nucleus accumbens to treat 8 heroin-addicted patients. Multiple
cortical and deep brain recording sessions were performed while
exposing the patients to either neutral or addiction-themed
images. Change in signal intensity with cortico-basal coherence
was used to identify the appropriate stimulation contact.
Identifying the appropriate stimulation setting was achieved by
asking the patient to engage in heroin “freebasing” behavior
(using real heroin), and to rate his/her experience with each of
the different settings used. At this writing, two patients have
been treated, and decreased addiction behavior was noted in
both patients with DBS stimulation. To be sure, these results are
preliminary, and continued work in this study—and others—will
be required to more accurately address and define the role and
value of DBS in treating addition disorders.
Highlights
- The “optimal” target for DBS in addiction is not established;
however, given extant data supporting the efficacy of nucleus
accumbens-directed DBS in treating OCD, and similar
cognitive and conative features of compulsive and addictive
behaviors, the nucleus accumbens has been considered as a
possible target.
- A study in the Netherlands that employed bilateral nucleus
accumbens DBS implantation to treat heroin addiction
demonstrated possible therapeutic benefits. At this point,
results are preliminary, and continued work in will be required
tomore accurately address and define the role and value of DBS
in treating addition disorders.
Use of DBS to Treat Post-Traumatic Stress
Disorder
Dis-inhibition and propagation of fear responses appear to
be cardinal neuro-cognitive features of PTSD (Furini et al.,
2014). Extinction of fear responses involves engagement of
the basolateral nucleus of the amygdala (BLn) and the medial
prefrontal cortex (mPFC) (Marek et al., 2013). Fear responses
(to even inert stimuli) can become heightened if this network
is compromised. In this event, progressive psychotherapeutic
approaches, such as progressive desensitization and/or stimulus
immersion are less likely to succeed. Pharmacotherapy using
benzodiazepines, while somewhat effective, is burdened by
side effects (inclusive of sedation, tolerance, and withdrawal),
and other pharmacological approaches (e.g., azapirones; beta-
receptor antagonists) have been shown to be only nominally
effective (Ravindran and Stein, 2010). In these cases, DBS of the
amygdala may be useful to suppress abnormal activity within
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amygdalar-prefrontocortical circuits, and “re-set” the inhibitory
tone necessary for fear extinction and reduction of PTSD
symptoms.
Langevin presented results of a 1-year study of a patient with
treatment-resistant PTSD who received BLn DBS. The patient
exhibited and reported significant improvements in all domains
of PTSD assessed (Langevin et al., 2016). In particular, the
patient reported and evidenced improved quality and quantity
of sleep (without nightmares), overall reduction in anxiety, fear
and irritability, and improvement in interpersonal interactions
with family members and work colleagues. Patient scores on
the clinician administered PTSD scale decreased in excess of
40%. There have been no treatment-related adverse events and,
in particular, monthly EEG studies have shown no evidence
of seizure or epileptiform activity. In addition, the monthly
EEG has shown progressively more sleep activity and improved
sleep architecture, with the patient showing increased deep
sleep that consistently occurs earlier in the patient’s sleep cycle.
Pre-operatively, the patient had undergone a fludeoxyglucose
(FDG) PET imaging studies, both at rest and under symptomatic
conditions during an exposure therapy session. These studies
revealed increased metabolic activity in the amygdala during the
symptomatic phase, as compared to the resting phase (Langevin
et al., 2016). The FDG PET study was repeated 1 year after
initiation of BLn DBS; post-treatment PET showed no difference
in amygdalar metabolic activity between the resting and the
symptomatic phase. This finding is consistent with patterns of
amygdalar activity during fear extinction, suggesting the efficacy
of BLn DBS in restoring a more normal pattern of activity in
amygdalar networks involved in cognitive and behavioral aspects
of fear that are representative of PTSD. The study is continuing,
with ongoing recruitment toward a target enrollment of six
patients.
Highlights
- A case was presented to support the possibility of using DBS
targeting the amygdalar BLn to reduce signs and symptoms of
PTSD
◦ Prior to DBS, the patient had disrupted sleep quality and
quantity, night terrors, OCD-like symptoms, and manifest
social disturbances. Following BLn DBS, the patient reports
feeling calmer, evidences improvement in sleep architecture
and quality (as demonstrated by EEG and described
through self-report), and describes improvement in social
interactions.
- FDG PET studies revealed post-DBS normalization of
metabolic activity in the amygdala metabolism.
Use of DBS to Treat Clinical Obesity
Clinical, morbid obesity is a significant public health problem,
both in the United States, and worldwide (Nangunoori et al.,
2016). The current standard of treatment for morbid obesity
that is not responsive to dietary and lifestyle modification, or
pharmacotherapy is bariatric surgery. However, bariatric surgery
although certainly of clinical value, also poses a number of risks,
and is not uniformly successful (Ho et al., 2015). In seeking
alternatives to gastro-intestinal surgery, DBS has been proposed
as a viable approach to affect hypothalamic mechanisms of
hunger and satiety that may be dysfunctional in morbidly obese
patients (Nangunoori et al., 2016).
To explore this possibility, three (3) patients with a history
of bariatric surgery were recruited; each with a current body
mass index (BMI) greater than 40 Kg/m2. The DBS target was
the bilateral lateral hypothalamus and post-operative images
confirmed successful electrode implantation in all cases. The
patients were followed for 2.5 years. The primary goal of this
study was to assess safety. There were no serious adverse effects
reported and no evidence of autonomic dysfunction. There was
a subjective report of decreased urge to eat. Although, the study
was not designed to assess efficacy, the resting metabolic rate was
measured using a metabolic chamber. It was noted that contacts
centered in the lateral hypothalamus were associated with an
increase in the resting metabolic rate. This, however, did not
correlate with a consistent weight loss (Whiting et al., 2013).
Long-term follow-up data were presented; one patient
dropped off due to delayed bariatric surgery complications.
During the long-term follow-up period, multiple DBS settings
(9 settings/day) were used to determine the optimal stimulation
parameters required to elicit the greatest increase in resting
metabolic rate. In one patient, BMI decreased from 46 to 38,
while the other patient did not show any weight loss or change in
BMI. However, both patients showed an increase in their resting
metabolic rate. The effects of any stimulation paradigm were
short-term. This was attributed to the “hedonic component of
food seeking and the motivational processes that drive eating”
(Whiting et al., 2013).
Future directions for studying the potential viability and value
of DBS to treat certain forms of clinical, morbid obesity are
centered upon the identification of other neurological targets
(e.g., the nucleus accumbens; see also Section DBS for Treatment
of Addiction, above; either singularly, or in combination with
stimulation of the lateral hypothalamus), and the potential utility
of employing closed-loop systems.
Highlights
- DBS to treat clinical morbid obesity has targeted the lateral
hypothalamus in an attempt to restore balance in hunger and
satiety states.
- In a limited study (n = 3), obese patients who had previously
undergone bariatric surgery and still maintained a BMI
> 40 Kg/m2 underwent DBS surgery targeting the lateral
hypothalamus.
- The procedure was noted to be safe in the 3 patients tested.
- Two years post-operatively, assessments indicate an increase
in the resting metabolic rate though this did not translate to
consistent weight loss.
- Future directions are focusing upon identification of other
and/or additional neuroanatomical targets for DBS to treat
clinical, morbid obesity.
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CONCLUSION
Herein we have summarized the presentations and discussion(s)
of the Fourth Annual DBS Think Tank. Policy and regulatory
issues and proposed optimizations were discussed, multiple
advances in the field were addressed, including updates on the
state of research, database and data registry, developments in
closed-loopDBS, themost current and novel applications of DBS,
and advances in electro-neurochemical sensing systems. In sum,
the field and applications of DBS are expanding, and to some
extent this expansion may represent a change in the status and
trajectory of DBS research and use in clinical practice. To assess
participants’ perspectives and attitudes toward the current and
near-term future development in the field, an anonymous 40
question poll was sent online at the conclusion of the Think Tank.
The questionnaire assessed the respondent’s perceived position of
DBS applications in disease states, neurotechnological principles,
and emerging applications on the hype cycle graph.
Thirty-six participants responded to the poll. These responses
are depicted in Figure 8. Of note is in contrast to last year,
participants’ current perception of some uses/indications for DBS
have slipped from the plateau of productivity to the slope of
enlightenment (e.g., Parkinson’s disease), others moved from
the trough of disillusionment to the contraction phase (e.g.,
Depression), still others moved from the expansion slope to the
peak of inflated expectations (e.g., Obesity).
In conclusion, the fourth Annual DBS Think Tank provided
a nexus for the presentation of new developments and findings,
discussion about the technology, research and practice of
DBS, and speculation about—and proposals for—the future
of the field. The future of DBS therapy will rely on
continuing innovation and cooperation of key stake and
shareholders, inclusive of scientists, engineers, physicians,
ethicists, administrators and policy makers. The aim of the
DBS Think Tank is to remain an important component of, and
resource for contributions to this process and progress.
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